Baseline demographic data of subjects
| Women | Men | |
| N | 44 | 101 |
| Age* | 67 (43–84) | 69 (45–88) |
| Ex-smokers (%) | 68 | 69 |
| Current smokers (%) | 30 | 29 |
| Pack year history* | 37 (10–100) | 54 (10–153) |
| Exacerbation rate prior to study entry* | 4 (1–12) | 3 (1–12) |
| BMI (kg/m2) | 27 (1.0) | 26 (0.4) |
| FFMI (kg/m2) | 16 (0.7) | 18 (0.2) |
| FEV1/FVC (%) | 55 (2) | 48 (2) |
| FEV1 (% predicted) | 57.2 (3.1) | 50.0 (2.0) |
| Reversibility (ml)* | 52 (−100–250) | 45 (−500–550) |
| Tlco (% predicted) | 55 (3) | 57 (3) |
| Kco (% predicted) | 69 (4) | 69 (3) |
| Long-acting β agonist (%) | 75 | 76 |
| Inhaled corticosteroid use | 86 | 86 |
| Inhaled corticosteroid dose (μg)† | 1250 (123) | 1362 (81) |
| Maintenance prednisolone (%) | 2 | 7 |
| Prednisolone dose (mg) | 10 (10) | 5 (4–10) |
| CRP (mg/l)‡ | 2.5 (6.5) | 6.0 (10.5) |
| Sputum neutrophils (%) | 69.2 (3.7) | 68.3 (2.3) |
| Sputum eosinophils¶ (%) | 1.2 (0.7 to 2.2) | 1.2 (0.9 to 1.7) |
BMI, body mass index; CRP, C-reactive protein; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; FFMI, fat-free mass index; Kco, carbon monoxide transfer coefficient; Tlco, carbon monoxide transfer factor.
Data presented as mean (SEM) unless otherwise indicated.
*Mean (range).
†BDP equivalent.
‡Median (IQR).
¶Geometric mean (95% CI).